CJC-1295 5 mg and IPAMORELIN 5 mg

CJC-1295 + Ipamorelin Overview

The CJC-1295 + Ipamorelin blend combines two peptides studied for their effects on endocrine signaling pathways. CJC-1295, a GHRH analog, is associated with sustained modulation of somatotroph axis activity and downstream signaling cascades. Ipamorelin, a selective secretagogue-type peptide, has been studied for its selective pituitary signaling activity without significant off-target pathway interference. Together, they may provide complementary activity across multiple endocrine and systemic pathways in experimental settings.

Teichman S.L. et al. (2006).

History

The concept of the CJC-1295 + Ipamorelin blend stems from parallel developments in peptide research aimed at exploring growth hormone modulation. CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways. Meanwhile, Ipamorelin—a selective ghrelin receptor agonist—emerged from studies in the 1990s investigating ghrelin mimetics and their ability to stimulate growth hormone release with minimal off-target hormonal effects. Together, these peptides became of interest for laboratory research into growth hormone regulation, recovery, and metabolic processes.

Svensson J. et al. (1998).

CJC-1295 + Ipamorelin Structure

CAS #:

446036-97-1

Molecular Formula:

C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight:

3367.9 g/mol

PubChem ID:

91976842